Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they are taking to ensure the COVID-19 vaccine programme is (1) resilient, and (2) stable, in terms of vaccine supply and product diversity; and whether they will avoid overreliance on one COVID-19 vaccine technology.

The United Kingdom has received sufficient supply of vaccines to meet the Joint Committee on Vaccination and Immunisation’s current advice for the autumn booster vaccination programme. This includes Pfizer/BioNTech and Moderna, with Novavax where no other UK-approved COVID-19 vaccine is deemed clinically suitable. These vaccines, which the Medicines and Healthcare products Regulatory Agency has approved for use in the UK, are currently in deployment.

The majority of the Government’s contracts with developers contain flexibilities to ensure that the UK can receive updated vaccines being produced, including the recently regulated bivalent mRNA vaccines, which provide broader protection against variants and variant-specific vaccines. We remain in regular contact with the vaccine manufacturers to ensure the future supply of vaccines to the UK.